Vitamin D, Calbindin, and calcium signaling: Unraveling the Alzheimer's connection.

Alzheimer's disease CAMK-II Calbindin Calcium binding protein Calcium signaling Calmodulin Vitamin D

Journal

Cellular signalling
ISSN: 1873-3913
Titre abrégé: Cell Signal
Pays: England
ID NLM: 8904683

Informations de publication

Date de publication:
09 Jan 2024
Historique:
received: 23 06 2023
revised: 21 12 2023
accepted: 08 01 2024
medline: 12 1 2024
pubmed: 12 1 2024
entrez: 11 1 2024
Statut: aheadofprint

Résumé

Calcium is a ubiquitous second messenger that is indispensable in regulating neurotransmission and memory formation. A precise intracellular calcium level is achieved through the concerted action of calcium channels, and calcium exerts its effect by binding to an array of calcium-binding proteins, including calmodulin (CAM), calcium-calmodulin complex-dependent protein kinase-II (CAMK-II), calbindin (CAL), and calcineurin (CAN). Calbindin orchestrates a plethora of signaling events that regulate synaptic transmission and depolarizing signals. Vitamin D, an endogenous fat-soluble metabolite, is synthesized in the skin upon exposure to ultraviolet B radiation. It modulates calcium signaling by increasing the expression of the calcium-sensing receptor (CaSR), stimulating phospholipase C activity, and regulating the expression of calcium channels such as TRPV6. Vitamin D also modulates the activity of calcium-binding proteins, including CAM and calbindin, and increases their expression. Calbindin, a high-affinity calcium-binding protein, is involved in calcium buffering and transport in neurons. It has been shown to inhibit apoptosis and caspase-3 activity stimulated by presenilin 1 and 2 in AD. Whereas CAM, another calcium-binding protein, is implicated in regulating neurotransmitter release and memory formation by phosphorylating CAN, CAMK-II, and other calcium-regulated proteins. CAMK-II and CAN regulate actin-induced spine shape changes, which are further modulated by CAM. Low levels of both calbindin and vitamin D are attributed to the pathology of Alzheimer's disease. Further research on vitamin D via calbindin-CAMK-II signaling may provide newer insights, revealing novel therapeutic targets and strategies for treatment.

Identifiants

pubmed: 38211841
pii: S0898-6568(24)00011-1
doi: 10.1016/j.cellsig.2024.111043
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111043

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declared no conflict of interest, financial or otherwise.

Auteurs

Manish Acharya (M)

Department of Neuropharmacology, School of Pharmaceutical Sciences, Shoolini University, Himachal Pradesh, India.

Nicky Singh (N)

Department of Neuropharmacology, School of Pharmaceutical Sciences, Shoolini University, Himachal Pradesh, India.

Gaurav Gupta (G)

School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Jaipur 302017, India.

Murtaza M Tambuwala (MM)

Lincoln Medical School, Universities of Nottingham and Lincoln College of Science, Brayford Pool Campus, Lincoln LN6 7TS. Electronic address: mtambuwala@lincoln.ac.uk.

Alaa A A Aljabali (AAA)

Faculty of Pharmacy, Department of Pharmaceutical Sciences, Yarmouk University, Irbid 21163, Jordan. Electronic address: alaaj@yu.edu.jo.

Dinesh Kumar Chellappan (DK)

Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia. Electronic address: dinesh_kumar@imu.edu.my.

Kamal Dua (K)

Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW 2007, Australia. Electronic address: kamal.dua@uts.edu.au.

Rohit Goyal (R)

Department of Neuropharmacology, School of Pharmaceutical Sciences, Shoolini University, Himachal Pradesh, India. Electronic address: rohitgoyal@shooliniuniversity.com.

Classifications MeSH